News
RCUS
15.55
+5.57%
0.82
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 1d ago
Arcus Biosciences To Present New Data From Phase 2 Studies Of Novel Immuno-Oncology Combinations At 2024 ASCO Annual Meeting
Data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal cancers will be presented in a special ASCO plenary series rapid abstract update session. Data from ARC-9 evaluating a colorectal cancer treatment combination will also be presented.
Benzinga · 2d ago
Press Release: Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update for the quarter ended March 31, 2024. Arcus is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer. The company will host a conference call and webcast on May 8, 2024 to discuss details of the Company's financial results.
Dow Jones · 3d ago
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
Arcus Biosciences will host a conference call and webcast on May 8th, 2024 to discuss details of the Company’s financial results and pipeline update for the quarter ended March 31st, 2024. Arcus is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer.
Barchart · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Verizon, Tesla, Vista Outdoor
U.S. Stocks poised to open higher on Monday. Easing Middle East tensions buoyed risk appetite. Dow e-minis up 0.56% at 38,421.75. Top three NYSE percentage gainers: Brunswick Corp, KB Financial, Vista Outdoor. Tesla down 4.3% premarket.
Reuters · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-EV stocks, Salesforce, Verizon
U.S. Stock index futures gain on Monday after slumping in the previous session. Easing Middle East tensions buoyed risk sentiment. Investors look ahead to major tech earnings and a key inflation print this week. Tesla shares fall after the company cuts prices. Salesforce up 3.4% in premarket.
Reuters · 4d ago
Weekly Report: what happened at RCUS last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at RCUS last week (0408-0412)?
Weekly Report · 04/15 09:19
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)
TipRanks · 04/12 10:50
Exelixis slips as Barclays downgrades on lack of catalysts
Barclays downgrades cancer drugmaker Exelixis on lack of catalysts. Lead asset cabozantinib faces a patent cliff, analyst says. Barclays sees better upside potential in other companies with similar pipelines. Exelxis shares traded lower on Thursday.
Seeking Alpha · 04/11 14:10
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. Is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer. The company granted 12 new employees options to purchase 45,000 shares of the Company’s common stock.
Barchart · 04/09 15:35
Weekly Report: what happened at RCUS last week (0401-0405)?
Weekly Report · 04/08 09:20
Top buy-rated stocks and sell-rated stocks within Health Care - Citi
Citi Research strategists have lowered the health care sector to underweight. The company has struggled with “uninspiring” growth in equipment and services. Pharmaceuticals, biotechnology and life sciences are the top sell-rated stocks within the sector. The top buy-rated stock is Arcus Biosciences.
Seeking Alpha · 04/04 15:12
Weekly Report: what happened at RCUS last week (0325-0329)?
Weekly Report · 04/01 09:20
*Arcus Biosciences Grants Four New Employees Options to Purchase Total of 18,400 Shrs >RCUS
Dow Jones · 03/26 20:35
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. Is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer. The company's Board of Directors granted four new employees options to purchase shares of the company's common stock.
Barchart · 03/26 15:35
Arcus Biosciences Price Target Maintained With a $50.00/Share by Truist Securities
Dow Jones · 03/25 16:05
Navigating 5 Analyst Ratings For Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The company has an average price target of $37.6 for the next 12 months. 5 analysts have provided ratings for Arcus B biosciences in the latest quarter. Arcus has been downgraded by 13.56% in the last 12 months from its average rating of 'buy' to 'neutral'
Benzinga · 03/25 16:01
Truist Securities Reiterates Buy on Arcus Biosciences, Maintains $50 Price Target
Benzinga · 03/25 15:54
Weekly Report: what happened at RCUS last week (0318-0322)?
Weekly Report · 03/25 09:20
More
Webull provides a variety of real-time RCUS stock news. You can receive the latest news about Arcus Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.